Singh and colleagues reported that an FDA-approved HDAC inhibitor vorinostat in combination with tranylcypromine, can reduce GBM stem cell viability in a GBM xenograft model and lead to changes in apoptosis-regulatory genes such as TP53 and TP73 [141]. The gene discussed is TP53; the disease is glioblastoma.